Parabilis Medicines (PBLS) Trading Update
Parabilis Medicines (PBLS) closed the trading session on Friday 23 September 2026 at a price of USD 26.92 per share, reflecting a 2.84 % increase over the preceding 24‑hour period. The share price was last recorded at 10:30 AM Central Europe.
Key Market Metrics
- Current share price: USD 26.92
- Outstanding shares: 123.5 million
- Market capitalization: USD 3.40 billion
- 24‑hour trading volume: USD 38.80 million
- Price change since month‑end: –27.04 %
- 200‑day simple moving average: USD 32.62
- 52‑week high: USD 42.49 (18 September 2026)
- 52‑week low: USD 22.66 (16 October 2026)
The 200‑day moving average indicates the stock is trading below its recent historical average, suggesting a downward trend relative to the longer‑term price action.
Related Corporate Developments
BB Biotech Third‑Quarter Report
BB Biotech released its third‑quarter results, confirming its long‑term investment thesis. Highlights include:
- Growth in net asset value (NAV).
- Share price outperformance relative to NAV and the Nasdaq Biotechnology Index.
- Portfolio companies secured U.S. drug approvals.
- Completion of two acquisitions: Crinetics Pharmaceuticals by Vertex and Nuvalent by GSK, with proceeds reinvested.
- Addition of twelve new holdings and divestiture of eight, bringing the portfolio to 43 companies.
- Continued use of an AI‑driven operating system to align scientific, clinical, and commercial data with valuation assumptions.
- Ongoing focus on sustainable NAV performance and active risk and capital allocation management.
Performance of Peer Stocks in the Past 24 Hours
| Ticker | % Change | Current Price (USD) | Market Capitalization (USD) | P/E Ratio |
|---|---|---|---|---|
| CRVL (Corvel) | +3.93 % | 83.88 | 4.1 bn | 35.94 |
| KTB (Kontoor Brands) | +0.07 % | 77.78 | 4.1 bn | 18.29 |
| SLGN (Silgan) | +2.05 % | 39.76 | 4.1 bn | 15.31 |
| DIOD (Diodes) | –8.10 % | 81.64 | 4.1 bn | 47.85 |
| INDV (Indivior) | +0.06 % | 35.33 | 4.1 bn | 12.60 |
Indivior is currently in the process of acquiring Supernus Pharmaceuticals. The transaction is expected to close shortly after regulatory approval. Upon completion, Supernus will be removed from the S&P SmallCap 600 and replaced by Huron Consulting Group. Indivior will remain listed but will no longer be a constituent of that index. This change is part of a broader reshuffling of the small‑cap index, which also includes the entry of MSG Rangers and the departure of Arbor Realty Trust. The acquisition is anticipated to strengthen Indivior’s position in the specialty‑pharma market, although its exact valuation impact has yet to be quantified.
